Information Provided By:
Fly News Breaks for September 21, 2017
ABMD
Sep 21, 2017 | 06:27 EDT
Jefferies analyst Raj Denhoy says pre-market approval clearance for its Impella RP heart pump system opens up a $375M market opportunity for Abiomed. The PMA and its "very broad label" should support more widespread and rapid adoption of RP, the analyst tells investors in a research note. Abiomed remains Denhoy's best growth story under coverage. He has a Buy rating on the shares with a $175 price target.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.